Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06068543 · ClinicalTrials.gov registry record · Phase 2
Reducing Frailty for Older Cancer Survivors Using Supplements II
A Phase 2 study of Inflammation and Frailty, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 1
- Study location
NCT06068543: Recruiting Phase 2 study of Inflammation and Frailty, sponsored by University of Rochester.
NCT06068543 is a Phase 2 study of Inflammation and Frailty that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 118 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06068543, a Phase 2 study of Inflammation and Frailty, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.
Conditions Studied
Interventions
- DRUG Epigallocatechin-3-Gallate (EGCG)
- DRUG Microcrystalline cellulose (MCC)
- DIETARY_SUPPLEMENT Ascorbic Acid (Vitamin C)
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
What NCT06068543 shows while recruiting
NCT06068543 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 3 interventions - of which Epigallocatechin-3-Gallate (EGCG) is the first listed.
NCT06068543 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06068543 about?
NCT06068543 is a clinical study titled "Reducing Frailty for Older Cancer Survivors Using Supplements II". This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.
What is the current status of trial NCT06068543?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2024-10-25. Estimated completion is 2030-12-31.
What conditions does trial NCT06068543 study?
This clinical trial studies the following conditions: Inflammation, Frailty.
What interventions are being tested in trial NCT06068543?
The interventions under investigation include: Epigallocatechin-3-Gallate (EGCG) (DRUG), Microcrystalline cellulose (MCC) (DRUG), Ascorbic Acid (Vitamin C) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06068543?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06068543 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06068543's enrollment target sits among peer trials
118 40th of 132 higher than 93 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI